DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Histologically or cytologically confirmed prostate carcinomas, urothelial carcinomas and clear cell renal carcinomas. For patients with prostate carcinomas, variant histologies, such as small cell or neuroendocrine carcinomas are permitted * Evidence of metastatic disease by conventional imaging studies (computed tomography \[CT\], magnetic resonance imaging \[MRI\] and/or bone scan). Patients with locally advanced disease that is not amenable to locoregional therapies such as surgery or radiation, are considered metastatic and eligible to participate * Patients with prostate carcinomas must have castration resistant disease, i.e. evidence of disease progression while having castrate levels of testosterone (=\< 50 ng/dL or =\< 2.0 nM) or an unsatisfactory response to \>= 1 month of castration, as defined by lack of symptom control and/or serum tumor marker response of \< 20% (confirmed by a second value drawn on a different day). Exception: patients with small cell carcinoma histology are not required to have progressed during prior androgen deprivation therapy. However, all patients with prostate cancer (including those with small cell carcinomas) are required to maintain castrate levels of testosterone throughout the duration of the study * Patients with prostate carcinomas must also display the AVPC molecular signature (i.e. known loss or mutation \[by Clinical Laboratory Improvement …